Merck Sharpe and Dohme affirms its commitment to cardiovascular care

Merck Sharpe and Dohme has reiterated its commitment to developing and marketing cardiovascular healthcare products.

The company has operated in this area over the last 50 years, introducing over 40 products targeting cardiovascular diseases.

It also offers a range of products and tools for cholesterol management and hypertension to address the needs of a wide range of patients.

Peter Kim, president of the firm’s research laboratories, said: “Today’s Merck has a robust portfolio and pipeline of cardiovascular medicines for conditions ranging from heart disease to metabolic syndrome.”

Earlier this month, Merck Sharpe and Dohme re-launched its business following its merger with Schering-Plough, revealing a more robust pipeline, greater global presence and a wider portfolio of products.

Richard Clark, chairman, president and chief executive officer of the organisation, said that the company now has a “clear vision for the future”.